EXEL vs. ISRG: A Head-to-Head Stock Comparison
Updated onHere’s a clear look at EXEL and ISRG, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.
Company Profile
| Symbol | EXEL | ISRG |
|---|---|---|
| Company Name | Exelixis, Inc. | Intuitive Surgical, Inc. |
| Country | United States | United States |
| GICS Sector | Health Care | Health Care |
| GICS Industry | Biotechnology | Health Care Equipment & Supplies |
| Market Capitalization | 11.09 billion USD | 158.13 billion USD |
| Exchange | NasdaqGS | NasdaqGS |
| Listing Date | April 17, 2000 | June 16, 2000 |
| Security Type | Common Stock | Common Stock |
Historical Performance
This chart compares the performance of EXEL and ISRG by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period. Data is adjusted for dividends and splits.
Historical Performance at a Glance
| Symbol | EXEL | ISRG |
|---|---|---|
| 5-Day Price Return | 6.14% | 0.73% |
| 13-Week Price Return | -6.30% | -17.70% |
| 26-Week Price Return | 11.59% | -12.14% |
| 52-Week Price Return | 59.09% | -6.67% |
| Month-to-Date Return | 10.37% | -5.51% |
| Year-to-Date Return | 24.02% | -14.32% |
| 10-Day Avg. Volume | 2.68M | 2.50M |
| 3-Month Avg. Volume | 3.08M | 2.04M |
| 3-Month Volatility | 42.93% | 24.85% |
| Beta | 0.33 | 1.61 |
Profitability
Return on Equity (TTM)
EXEL
27.74%
Biotechnology Industry
- Max
- 97.92%
- Q3
- 11.99%
- Median
- -19.30%
- Q1
- -51.29%
- Min
- -132.03%
In the upper quartile for the Biotechnology industry, EXEL’s Return on Equity of 27.74% signals a highly effective use of shareholder capital to drive profitability compared to most of its peers.
ISRG
15.55%
Health Care Equipment & Supplies Industry
- Max
- 29.93%
- Q3
- 16.99%
- Median
- 9.28%
- Q1
- 5.10%
- Min
- -12.52%
ISRG’s Return on Equity of 15.55% is on par with the norm for the Health Care Equipment & Supplies industry, indicating its profitability relative to shareholder equity is typical for the sector.
Net Profit Margin (TTM)
EXEL
27.01%
Biotechnology Industry
- Max
- 73.34%
- Q3
- 18.98%
- Median
- -12.96%
- Q1
- -105.72%
- Min
- -259.82%
A Net Profit Margin of 27.01% places EXEL in the upper quartile for the Biotechnology industry, signifying strong profitability and more effective cost management than most of its peers.
ISRG
28.51%
Health Care Equipment & Supplies Industry
- Max
- 24.41%
- Q3
- 13.71%
- Median
- 10.08%
- Q1
- 5.96%
- Min
- -5.58%
ISRG’s Net Profit Margin of 28.51% is exceptionally high, placing it well beyond the typical range for the Health Care Equipment & Supplies industry. This demonstrates outstanding operational efficiency and a strong competitive advantage in converting revenue into profit.
Operating Profit Margin (TTM)
EXEL
31.38%
Biotechnology Industry
- Max
- 78.85%
- Q3
- 21.90%
- Median
- -13.30%
- Q1
- -109.94%
- Min
- -278.10%
An Operating Profit Margin of 31.38% places EXEL in the upper quartile for the Biotechnology industry. This signals a strong ability to translate revenue into operating profit, outperforming most of its competitors in core business efficiency.
ISRG
28.80%
Health Care Equipment & Supplies Industry
- Max
- 31.09%
- Q3
- 18.11%
- Median
- 15.07%
- Q1
- 8.48%
- Min
- -0.28%
An Operating Profit Margin of 28.80% places ISRG in the upper quartile for the Health Care Equipment & Supplies industry. This signals a strong ability to translate revenue into operating profit, outperforming most of its competitors in core business efficiency.
Profitability at a Glance
| Symbol | EXEL | ISRG |
|---|---|---|
| Return on Equity (TTM) | 27.74% | 15.55% |
| Return on Assets (TTM) | 21.09% | 13.75% |
| Net Profit Margin (TTM) | 27.01% | 28.51% |
| Operating Profit Margin (TTM) | 31.38% | 28.80% |
| Gross Profit Margin (TTM) | 96.59% | 66.61% |
Financial Strength
Current Ratio (MRQ)
EXEL
3.51
Biotechnology Industry
- Max
- 16.97
- Q3
- 8.39
- Median
- 4.11
- Q1
- 2.64
- Min
- 0.74
EXEL’s Current Ratio of 3.51 aligns with the median group of the Biotechnology industry, indicating that its short-term liquidity is in line with its sector peers.
ISRG
5.64
Health Care Equipment & Supplies Industry
- Max
- 5.19
- Q3
- 3.00
- Median
- 2.13
- Q1
- 1.44
- Min
- 0.86
ISRG’s Current Ratio of 5.64 is exceptionally high, placing it well outside the typical range for the Health Care Equipment & Supplies industry. This indicates a very strong liquidity position, though such a high ratio may also suggest that the company is not using its assets efficiently to generate profits.
Debt-to-Equity Ratio (MRQ)
EXEL
0.00
Biotechnology Industry
- Max
- 1.92
- Q3
- 0.79
- Median
- 0.12
- Q1
- 0.00
- Min
- 0.00
EXEL’s Debt-to-Equity Ratio of 0.00 is typical for the Biotechnology industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.
ISRG
0.00
Health Care Equipment & Supplies Industry
- Max
- 1.61
- Q3
- 0.76
- Median
- 0.45
- Q1
- 0.14
- Min
- 0.00
Falling into the lower quartile for the Health Care Equipment & Supplies industry, ISRG’s Debt-to-Equity Ratio of 0.00 points to a conservative financing strategy. This results in lower financial risk but potentially limits strategic investments compared to more leveraged competitors.
Interest Coverage Ratio (TTM)
EXEL
42.74
Biotechnology Industry
- Max
- 72.37
- Q3
- 1.03
- Median
- -9.59
- Q1
- -65.05
- Min
- -163.11
EXEL’s Interest Coverage Ratio of 42.74 is in the upper quartile for the Biotechnology industry, signifying a strong and healthy capacity to meet its interest payments from operating profits.
ISRG
--
Health Care Equipment & Supplies Industry
- Max
- 56.35
- Q3
- 25.56
- Median
- 9.60
- Q1
- 3.78
- Min
- -26.49
Interest Coverage Ratio data for ISRG is currently unavailable.
Financial Strength at a Glance
| Symbol | EXEL | ISRG |
|---|---|---|
| Current Ratio (MRQ) | 3.51 | 5.64 |
| Quick Ratio (MRQ) | 3.22 | 4.89 |
| Debt-to-Equity Ratio (MRQ) | 0.00 | 0.00 |
| Interest Coverage Ratio (TTM) | 42.74 | -- |
Growth
Revenue Growth
EPS Growth
Dividend
Dividend Yield (TTM)
EXEL
0.00%
Biotechnology Industry
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
EXEL currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.
ISRG
0.00%
Health Care Equipment & Supplies Industry
- Max
- 4.15%
- Q3
- 1.76%
- Median
- 0.79%
- Q1
- 0.00%
- Min
- 0.00%
ISRG currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.
Dividend Payout Ratio (TTM)
EXEL
0.00%
Biotechnology Industry
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
EXEL has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.
ISRG
0.00%
Health Care Equipment & Supplies Industry
- Max
- 160.00%
- Q3
- 66.60%
- Median
- 27.49%
- Q1
- 0.00%
- Min
- 0.00%
ISRG has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.
Dividend at a Glance
| Symbol | EXEL | ISRG |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 0.00% |
| Dividend Payout Ratio (TTM) | 0.00% | 0.00% |
Valuation
Price-to-Earnings Ratio (TTM)
EXEL
18.37
Biotechnology Industry
- Max
- 40.44
- Q3
- 39.37
- Median
- 22.12
- Q1
- 15.76
- Min
- 3.48
EXEL’s P/E Ratio of 18.37 is within the middle range for the Biotechnology industry. This suggests its valuation is in line with the sector average, representing neither a significant premium nor a discount compared to its peers.
ISRG
61.32
Health Care Equipment & Supplies Industry
- Max
- 67.29
- Q3
- 47.01
- Median
- 30.94
- Q1
- 23.91
- Min
- 10.79
A P/E Ratio of 61.32 places ISRG in the upper quartile for the Health Care Equipment & Supplies industry. This high valuation relative to peers suggests the market holds elevated expectations for the company’s future growth.
Price-to-Sales Ratio (TTM)
EXEL
4.96
Biotechnology Industry
- Max
- 92.67
- Q3
- 41.36
- Median
- 8.45
- Q1
- 4.46
- Min
- 0.97
EXEL’s P/S Ratio of 4.96 aligns with the market consensus for the Biotechnology industry. This suggests its valuation, based on sales, is seen as standard and is on par with its competitors.
ISRG
17.49
Health Care Equipment & Supplies Industry
- Max
- 9.49
- Q3
- 5.41
- Median
- 2.86
- Q1
- 2.07
- Min
- 0.74
With a P/S Ratio of 17.49, ISRG trades at a valuation that eclipses even the highest in the Health Care Equipment & Supplies industry. This implies the market has priced in exceptionally optimistic scenarios for future revenue growth, posing considerable valuation risk.
Price-to-Book Ratio (MRQ)
EXEL
6.19
Biotechnology Industry
- Max
- 22.72
- Q3
- 10.68
- Median
- 4.55
- Q1
- 2.44
- Min
- 0.59
EXEL’s P/B Ratio of 6.19 is within the conventional range for the Biotechnology industry. This shows a balanced market view, where the stock’s price is neither at a significant premium nor a discount to the book value of its peers.
ISRG
10.85
Health Care Equipment & Supplies Industry
- Max
- 10.85
- Q3
- 6.56
- Median
- 3.53
- Q1
- 2.36
- Min
- 0.71
ISRG’s P/B Ratio of 10.85 is in the upper tier for the Health Care Equipment & Supplies industry. This indicates that investors are paying a premium relative to the company’s net assets, a valuation that hinges on its ability to generate superior profits.
Valuation at a Glance
| Symbol | EXEL | ISRG |
|---|---|---|
| Price-to-Earnings Ratio (TTM) | 18.37 | 61.32 |
| Price-to-Sales Ratio (TTM) | 4.96 | 17.49 |
| Price-to-Book Ratio (MRQ) | 6.19 | 10.85 |
| Price-to-Free Cash Flow Ratio (TTM) | 14.67 | 80.18 |